Laboratory Lab results are too important to go anywhere else.

Pancreastatin, Plasma

Test Codes

EPIC: LAB6312, Beaker: XPANC, Mayo: FPANP

Department

Send Outs

Instructions

• Patient must be fasting 10-12 hours prior to collection of specimen.
• Patient should not be on any medications that may influence Insulin levels, if possible, for at least 48 hours prior to collection.

Specimen Collection Criteria

Collect (preferred specimen): Z-tube (MCL T701) (Minimum 1.0 mL)

• Draw 10.0 mL of blood in special Z-tube, pre-chilled (MCL T701).
• Separate plasma from cells immediately after draw and freeze immediately after separation.
• Send 3.0 mL of plasma in frozen plastic vial. (Minimum 1.0 mL).

Critical frozen. Send specimens for processing immediately after collection.

Physician Office/Draw Specimen Preparation

Critical frozen. Centrifuge to separate plasma from cells. Transfer plasma to plastic transport tube and freeze (-20°C/-4°F or below) immediately.

Preparation for Courier Transport

Transport: 3.0 mL plasma frozen (-20°C/-4°F or below). (Minimum: 1.0 mL)

Rejection Criteria

In-Lab Processing

Critical frozen. Centrifuge to separate plasma from cells. Transfer plasma to plastic transport tube and freeze (-20°C/-4°F or below) immediately.

Transport: 3.0 mL plasma, frozen (-20°C/-4°F or below). (Minimum: 1.0 mL)

Storage

Specimen Stability for Testing:

Room Temperature (20-26°C or 68-78.8°F): Unacceptable
Refrigerated (2-8°C or 36-46°F): Unacceptable
Frozen (-20°C/-4°F or below): 30 days

Specimen Storage in Department Prior to Disposal:

Specimen retention time is determined by the policy of the reference laboratory. Contact the Send Outs Laboratory with any questions.

Laboratory

Sent to Mayo Medical Laboratories, Rochester, MN, forwarded to Cambridge Biomedical, Boston, MA.

Performed

Mondays.
Results available within 8-12 days.

Reference Range

By report.

Test Methodology

Direct Radioimmunoassay.

Interpretation

By report.

Clinical Utility

Pancreastatin is a 49 amino acid peptide produced by degradation of chromogranin A. It inhibits chromogranin A and parathyroid hormone release. Pancreastatin also inhibits release of somatostatin upon glucose stimulation. It may also control carbohydrate metabolism and hyperglycemia. Pancreastatin reduces the early phase of glucose induced insulin release. Suppression of insulin release upon glucose stimulation is a characteristic feature of Type-2 diabetes. Pancreastatin could play an important therapeutic role in the treatment of diabetes. Pancreastatin also inhibits the release of somatostatin. It may also control carbohydrate metabolism and hyperglycemia.

CPT Codes

86316

Contacts

Last Updated

10/8/2023